In 2017, Novo Nordisk launched Ozempic and unknowingly started the GLP-1 drug war that would reshape the pharmaceutical industry forever. Nobody quite predicted what would happen next.
By 2024, GLP-1 drugs had become the most talked-about pharmaceutical products in history. Celebrities endorsed them. Waiting lists stretched for months. Insurance companies scrambled to decide whether to cover them. And two pharmaceutical giants, Novo Nordisk and Eli Lilly found themselves locked in the most commercially consequential drug war of the 21st century.
But here is what makes this story genuinely fascinating from a business analytics perspective: this is not a battle being decided in laboratories alone. It is being decided by data like clinical trial data, market share data, prescription analytics, manufacturing throughput data, and advertising effectiveness data. Understanding how both companies are using analytics to compete tells you as much about modern business strategy as it does about pharmaceutical science.
What We Are Actually Talking About
GLP-1 (glucagon-like peptide-1) drugs work by mimicking a hormone that regulates appetite and blood sugar. The result is significant, sustained weight loss, something the pharmaceutical industry had been trying to achieve safely for decades. The market opportunity is staggering. Approximately 1 billion people worldwide are classified as obese. The global GLP-1 market is projected to reach $130 billion by 2030. And right now, two companies control virtually all of it.
Novo Nordisk — the Danish pharmaceutical giant was first to market. Its injectable drugs Ozempic (diabetes) and Wegovy (obesity) defined the category. By mid-2025, Novo Nordisk held a 59.6% branded volume market share in the global obesity GLP-1 market and a 62.1% share across both diabetes and obesity combined.
Eli Lilly — the American pharmaceutical giant entered later with Mounjaro (diabetes) and Zepbound (obesity). But Lilly entered with a better drug, one that demonstrably outperforms Novo’s products on the metric that matters most to patients: weight loss.
The market share shift that followed is one of the most dramatic in modern pharmaceutical history.
Global GLP-1 market size projected to reach $130B by 2030. Source: J.P. Morgan Healthcare Research
Descriptive Analytics
Descriptive analytics answers the question: what happened? It is the foundation of any business analytics framework understanding the current state before making predictions or decisions.
The descriptive picture of the GLP-1 market in 2026 is striking.
Novo Nordisk was first to market in every meaningful sense. Ozempic launched in 2017 for diabetes. Wegovy launched in 2021 for obesity. By early 2024, Novo had an overwhelming first-mover advantage, brand recognition, prescriber relationships, and a loyal patient base built over years.
Then Lilly’s head-to-head clinical trial changed everything. In a direct comparison of Zepbound versus Wegovy, patients on Zepbound lost an average of 50 pounds in 72 weeks. Patients on Wegovy lost 33 pounds in the same period. That is a 52% superior outcome on the primary endpoint, not a marginal difference, but a clinically and commercially significant one.
The market responded with remarkable speed. By June 2024, Lilly’s US prescriptions were rising while Novo’s were declining. By February 2025, Lilly had overtaken Novo in the US market. As of mid-2026, Lilly holds approximately 60% of the US GLP-1 market. The financial divergence is equally dramatic. Lilly forecasted 2026 sales of $80 to $83 billion that is 25% growth, surpassing analyst expectations. Novo warned of a 5 to 13% sales decline in 2026, as prices fall in the US and drug exclusivity expires in major markets including China, Brazil and Canada.
This is descriptive analytics at its most powerful: the numbers tell a clear story of a market leader losing ground to a better-performing competitor.
Watch Eli Lilly overtake Novo Nordisk in US market share from 2021 to 2026
Business Intelligence
Business Intelligence (BI) refers to the systems, processes and technologies that collect, analyze and present business data to support decision-making. In the GLP-1 market, both Novo and Lilly are deploying sophisticated BI infrastructure to track their competitive position in real time.
The primary data source for the pharmaceutical industry is IQVIA, the world’s largest healthcare data and analytics company. Both Novo and Lilly reference IQVIA data extensively in their earnings reports and investor communications, tracking moving annual totals of prescription volumes, market share by geography, and patient persistence rates.
What makes this interesting from a BI perspective is how differently the two companies interpret the same data. Novo Nordisk’s Q1 2026 results showed Wegovy pill generating 1.3 million prescriptions and $355 million in revenues, nearly double analysts’ $182 million projection. Novo’s BI systems flagged this as a major win and the company publicly celebrated the launch momentum.
Lilly’s BI systems were simultaneously tracking the same market through a different lens: total addressable market penetration rather than absolute prescription counts. Lilly reported $4.2 billion in Zepbound sales in Q1 2026, up 80% year over year. Its BI dashboard was showing not just current share but trajectory, and the trajectory clearly favored Lilly.
The lesson here is a fundamental principle of business intelligence: the same data, framed differently, tells different stories. The company that builds BI systems aligned to the right strategic questions not just the flattering ones which gains a genuine competitive advantage.
Predictive Analytics
If descriptive analytics tells you what happened, predictive analytics tells you what is likely to happen next. And the next battleground in the GLP-1 war that is already underway, is oral pills. Both companies have launched or are launching oral versions of their weight loss drugs, and the analytical picture here is genuinely uncertain.
Novo Nordisk launched its oral Wegovy pill first, and the early data was impressive. The pill reached 50,000 weekly prescriptions in just under three weeks of launch and hit 2 million total prescriptions by April 17, 2026, with more than 200,000 prescriptions in a single week. Novo’s predictive models suggested the oral format would dramatically expand the addressable market by removing the barrier of weekly injections.
But Lilly’s oral candidate orforglipron, carries a potentially decisive analytical advantage. Novo’s pill is a peptide medication requiring patients to drink no more than four ounces of water at administration and wait 30 minutes before eating or drinking anything else each day. Lilly’s orforglipron is a small-molecule drug absorbed more easily in the body without these dietary restrictions.
From a predictive analytics standpoint, patient adherence data is the critical variable. Pharmaceutical analytics consistently shows that adherence rates, the percentage of patients who continue taking a drug as prescribed are the single strongest predictor of long-term commercial success in chronic disease management. A drug that is marginally less effective but dramatically easier to take consistently will often outperform a superior drug with adherence challenges. Predictive models from independent analysts suggest Lilly’s oral pill could generate greater global sales than Novo’s, precisely because the convenience differential will translate into better adherence data and adherence data drives prescriber behavior.
GLP-1 drug comparison: Zepbound leads on both weight loss outcomes and market share
Machine Learning and Decision Trees
Here is the dimension of this story that most business coverage misses entirely: the GLP-1 war is not just a scientific and marketing competition. It is an industrial and logistics competition and both companies are using machine learning to try to win it.
For most of 2022 to 2024, demand for GLP-1 drugs dramatically outstripped supply. Patients faced months-long waiting lists. Pharmacies ran out of stock. Compounding pharmacies producing unofficial generic versions flourished in the gap. This supply crisis cost both companies enormous amounts of revenue and damaged patient trust. Both Novo and Lilly have since made extraordinary manufacturing investments. Lilly has committed more than $50 billion to new manufacturing sites and expansions since 2020, announcing 10 US manufacturing sites. Novo has made comparable investments globally.
The analytics challenge is using machine learning to optimize this manufacturing capacity. A decision tree model for pharmaceutical manufacturing prioritization might look like this:
- At the top level: is this a new or existing patient? New patients represent growth; existing patients represent retention and revenue stability. Both are critical inputs to manufacturing volume planning.
- At the second level: what geography? Markets with insurance coverage generate different demand curves than out-of-pocket markets. Machine learning models trained on prescription data, insurance coverage changes, and demographic trends can predict regional demand with increasing accuracy.
- At the third level: what formulation? Injectable versus oral, weekly versus daily, branded versus soon-to-be-generic, the manufacturing decision tree branches into hundreds of scenarios, each with different capacity requirements, margin profiles, and strategic priorities.
Both companies are using machine learning systems to navigate this decision tree in real time, adjusting production schedules, inventory positioning, and supply chain routing based on prescription data that updates weekly through IQVIA feeds. The company that wins the manufacturing analytics battle by producing the right drugs in the right quantities in the right locations will have a structural cost and availability advantage that clinical superiority alone cannot overcome.
Reading the Market Signal
One of the most instructive data points in this entire story is advertising spend.
In 2025, total GLP-1 drug advertising hit $1.1 billion, nearly one-fifth of all pharmaceutical advertising in the US. Wegovy alone spent $501 million on national TV ads. Zepbound spent $284 million. Ozempic spent $200 million. Mounjaro spent $156 million.
This advertising data tells a story that clinical trial results alone cannot. The GLP-1 market has crossed a threshold: it is no longer primarily a physician-driven market where prescribers educate patients about treatment options. It has become a consumer-driven market where patients arrive at doctor’s offices having already decided they want a specific drug by name. When a pharmaceutical market crosses this threshold, the analytics of competition shift fundamentally. Clinical outcomes data, the traditional currency of pharma competition becomes necessary but not sufficient. Brand analytics, social media sentiment, consumer awareness metrics, and advertising effectiveness data become equally important competitive intelligence.
Novo Nordisk’s 2025 advertising dominance, spending 76% more than Lilly on TV ads, reflects its recognition of this shift. But Lilly’s superior clinical data means its advertising investment converts at a higher rate: prescribers who hear “my patient wants Zepbound” face an easier decision when they also know Zepbound produces 52% better weight loss outcomes.
The Ground Floor Take
The Novo Nordisk versus Eli Lilly story is one of the most analytically rich competitive battles in modern business and the outcome remains genuinely uncertain.
The descriptive analytics favor Lilly right now: better market share trajectory, stronger revenue growth, and superior clinical outcomes data. The predictive analytics also lean Lilly, particularly if orforglipron’s adherence advantage proves as significant as the early signals suggest.
But Novo is not finished. Its global market leadership outside the US remains substantial. Its first-mover advantage in oral GLP-1 pills may prove more durable than critics expect. And its pipeline including next-generation drugs like amycretin, could reset the clinical comparison entirely.
What is certain is that neither company is making decisions based on intuition alone. This is a war being fought with data, prescription analytics, manufacturing optimization models, advertising effectiveness dashboards, patient adherence algorithms, and competitive intelligence systems tracking every IQVIA data release. The winner will not simply be the company with the better drug. It will be the company that uses data more intelligently across every dimension of its business from clinical development to manufacturing to marketing to patient support.
In that sense, the GLP-1 war is not just a pharmaceutical story. It is a masterclass in what business analytics actually looks like when the stakes are high enough to demand the very best of it.
